Abstract Details

Title Evaluation of the Safety Profile of the Tirofiban Protocol for Select Patients with Acute Ischemic Stroke at a United States Comprehensive Stroke Center

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P8 - Poster Session 8 (11:45 AM-12:45 PM)

Poster/Presentation
Number 4-013

Objective To evaluate the safety, feasibility and efficacy of the administration of tirofiban in RESCUE BT2 eligible patients at a United States comprehensive stroke center.

Background Tirofiban has been studied as an adjunctive treatment in patients with acute ischemic stroke. In the recent RESCUE BT2 trial, intravenous (IV) tirofiban in patients without medium or large vessel occlusions was associated with an improvement in functional outcomes compared to aspirin monotherapy, though with slightly higher incidence of intracranial hemorrhage. The majority of studies regarding tirofiban were performed in a majority Han Chinese population.

Design/Methods This single-center retrospective study analyzed the electronic medical records of patients who were treated with tirofiban per RESCUE BT2 protocol, from November 2023 to June 2025. Clinical safety outcomes included 90-day mortality rate, asymptomatic or symptomatic ICH within 48 hours following treatment, tirofiban-induced thrombocytopenia, and extracranial bleeding. Clinical outcomes were assessed using the National Institute of Health Stroke Scale (NIHSS) scores at discharge, and modified Rankin Score (mRS) at discharge and 90 days.

Results A total of 32 patients, with a median NIHSS of 7 at the time of early neurological deterioration received tirofiban, were included. Most patients had either small vessel or large artery atherosclerotic disease. While 3 of the patients who received tirofiban, with 53% (N = 17) of patients receiving preceding antiplatelet therapy, had extracranial bleeding (nasal mucosal and gastrointestinal tract), none of the patients had asymptomatic or symptomatic ICH within 48 hours of treatment or tirofiban-induced thrombocytopenia. One patient died, but it was not attributed to tirofiban. At discharge, the median NIHSS was 5 and the median mRS was 4. The median mRS at 90 days was 3.

Conclusions This study demonstrated that IV tirofiban has a favorable safety profile in a Western population with recent onset or progression of stroke symptoms and non-occluded medium and large-sized cerebral vessels.

Authors/Disclosures
Kevin W. Dang, MD PRESENTER	Dr. Dang has nothing to disclose.
Josiah Chang, MD (Barrow Neurological Institute)	Dr. Chang has nothing to disclose.
David Z. Wang, DO, FAHA, FAAN (BNI, Neurology, Stroke)	Dr. Wang has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Mediwelcome.
Supreet Kaur, MD	Dr. Kaur has nothing to disclose.

��ɫ��

��ɫ��